[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@seahorse_anton Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1986901942216630272.png) @seahorse_anton Dr Anton_Invests

Dr Anton_Invests posts on X about strong, $mrna, bearish, momentum the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1986901942216630272/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1986901942216630272/c:line/m:interactions.svg)

- X Week XXXXX -XX%

### Mentions: XX [#](/creator/twitter::1986901942216630272/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1986901942216630272/c:line/m:posts_active.svg)

- X Week XX no change

### Followers: XX [#](/creator/twitter::1986901942216630272/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1986901942216630272/c:line/m:followers.svg)

- X Week XX +16%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1986901942216630272/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1986901942216630272/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  XXXXX% [finance](/list/finance)  XXXXX% [countries](/list/countries)  XXXX% [currencies](/list/currencies)  XXXX% [technology brands](/list/technology-brands)  XXXX% [travel destinations](/list/travel-destinations)  XXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX%

**Social topic influence**
[strong](/topic/strong) 14.52%, [$mrna](/topic/$mrna) #10, [bearish](/topic/bearish) #419, [momentum](/topic/momentum) #896, [bullish](/topic/bullish) 3.23%, [business](/topic/business) 3.23%, [$ttr](/topic/$ttr) #1, [$oscr](/topic/$oscr) #102, [$tigr](/topic/$tigr) #27, [$rxrx](/topic/$rxrx) #23

**Top accounts mentioned or mentioned by**
[@ckcryptoklepto](/creator/undefined) [@syndrome22q1](/creator/undefined) [@catturd2](/creator/undefined) [@gunthereagleman](/creator/undefined) [@karolineleavitt](/creator/undefined) [@atensnut](/creator/undefined) [@lindayax](/creator/undefined) [@dbongino](/creator/undefined) [@bennyjohnson](/creator/undefined) [@alphafox](/creator/undefined) [@mrbeast](/creator/undefined)

**Top assets mentioned**
[Moderna Inc (MRNA)](/topic/$mrna) [Oscar Health, Inc. (OSCR)](/topic/$oscr) [Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)](/topic/$rxrx) [SAP SE (SAP)](/topic/$sap) [Nu Holdings Ltd. (NU)](/topic/nu-holdings) [NuCypher (NU)](/topic/$nu) [CoreWeave, Inc. (CRWV)](/topic/$crwv) [Richtech Robotics Inc. Class B Common Stock (RR)](/topic/richtech-robotics) [retard to retired (R/R)](/topic/$rr) [ZetaChain (ZETA)](/topic/$zeta) [AstraZeneca PLC (AZN)](/topic/$azn) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn)
### Top Social Posts
Top posts by engagements in the last XX hours

"$SAP Weekly Ichimoku Breakdown The German software giant - Do not go. Last XX candles show a strong downside acceleration: a clean rejection from $XXX consecutive heavy red candles this week breaking the 100W EMA ($237.49) and landing right on the 200W EMA ($236.70). Bearish momentum fully active. Price is well below Tenkan ($257.44) and below Kijun ($266.86) both sharply downsloping confirms short-term and mid-term bearish trend dominance. Price has fallen below the cloud and the cloud ahead is bearish wide and thickening signaling a confirmed trend reversal from bullish bearish unless price"  
[X Link](https://x.com/seahorse_anton/status/1992587893504606506)  2025-11-23T13:35Z XX followers, XX engagements


"From Overbought to Opportunity: A Multi-Timeframe Strategy for Buying the Dip in $NU Dominant Uptrend. Nu Holdings Ltd - South America The Hook: Strong Trend Bad Entry $NU ALERT: Don't Chase the New Highs. Price is Overbought. The Weekly chart shows NU is in a perfect healthy uptrend. Volume is surging (OBV Z-Score +2.0). Fundamentals are bullish (18 USD target). But our 4H RSI is XXXX (Overbought). The risk/reward for a fresh entry is poor (0.95x). Strategy: WAIT for the pullback. The Trend Structure The weekly chart is a perfect continuation setup: Price is far above Tenkan (16.20 $) and"  
[X Link](https://x.com/seahorse_anton/status/1995974993067606234)  2025-12-02T21:54Z XX followers, XXX engagements


"Key Financial Insight: $MRNA Reliance on Royalties: Modernas current business model is focused on paying royalties (third-party royalties included in Cost of Sales) rather than receiving them though they do receive them through partnerships like AstraZeneca. Declining Collaboration: As the company matures and the pipeline advances toward commercialization the proportion of Collaboration Revenue to Product Sales has drastically shrunk confirming its transition into a product-driven biopharma company. Strategic Priorities & Business Model Recent Shift As of their 2025 guidance Moderna plans to"  
[X Link](https://x.com/seahorse_anton/status/1998827968525681009)  2025-12-10T18:51Z XX followers, XX engagements


"Quant + Momentum Breakdown: $TTR Weekly Quant View Strong Bearish Our TBM/HAC model prints XXXX with a bearish regime and weak R/R (0.6). MACD RSI OBV Z-score and volume internals all confirm momentum decay + distribution. Chikou spans below price/cloud trend intact. Neutral drift dominates but downside volatility is still expanding"  
[X Link](https://x.com/seahorse_anton/status/1997636455766642867)  2025-12-07T11:57Z XX followers, XXX engagements


"What It Means Strategic Implications $MRNA Modernas path shifting from a one-hit vaccine success into a broad mRNA-based medicine company is ambitious and high-stakes. If they manage to: build a sustainable seasonal vaccine business prove efficacy in oncology or rare-disease mRNA therapies keep costs under control they can emerge as a diversified next-generation biotech platform not just a vaccine-maker. But that path demands high execution discipline regulatory success and scientific breakthroughs. Given the across-the-board ambitions (vaccines oncology rare diseases) Moderna embodies"  
[X Link](https://x.com/seahorse_anton/status/1998827975446294863)  2025-12-10T18:51Z XX followers, XX engagements


"Competition By Sector & Technology Moderna does not have a single competitive set; it has four distinct arenas with completely different rivals and threat profiles: a) Respiratory & Infectious Disease Vaccines (COVID Flu RSV Combo vaccines) This is Modernas largest near-term revenue base and also the sector with the fiercest competition. Competitors: Traditional vaccine developers other mRNA- and non-mRNA-based vaccine makers. Challenges: As demand normalizes post-pandemic pricing pressure regulatory scrutiny and market saturation increase. Opportunity: Influenza RSV and other seasonal"  
[X Link](https://x.com/seahorse_anton/status/1998827979233775908)  2025-12-10T18:51Z XX followers, XX engagements


"$OSCR sits just under resistance with a bearish daily cloud and weak ML probability (17%). 4H confirmation is also weak (25) and volume is leaning negative (CMF 0.08). Overall Not a strong long setup. Needs momentum + volume shift. (D) Daily Breakout Forecast Close: $XXXXX Support: $XXXXX Resistance: $XXXXX RSI: XXXX MACD: XXXX bull histogram OBV Z-Score: XXX (Neutral/Bullish Threshold) ML Breakout UP Probability (5 days): XX% 🟢 Cloud: Bearish Trend: Neutral Tip: Low ML + bearish cloud = breakout unlikely without 4H strength. (4H) Intraday Confirmation Close: $XXXXX Support: $16.37"  
[X Link](https://x.com/seahorse_anton/status/1996664004060565533)  2025-12-04T19:32Z XX followers, XXX engagements


"My Take: $TIGR is pushing above resistance around the Q3 report with ML showing a bullish XX% breakout probability but the daily cloud is still not sure meaning structure hasnt turned yet. 4H shows a strong XX confirmation score boosted by a volatility-hole signal but VPT divergence warns of weak volume support. Overall High short-term momentum but cloud + volume divergence = not clean breakout yet. Trying to push further. (D) Daily Breakout Forecast Close: $XXXX Support: $XXXX Resistance: $XXXX RSI: XXXX MACD: XXXX histogram +0.04 (bullish inflection) OBV Z-Score: XXX Neutral flow ML"  
[X Link](https://x.com/seahorse_anton/status/1996675851912446280)  2025-12-04T20:19Z XX followers, XXX engagements


"UP Fintech $TIGR reported record-high revenue and profit for Q3 2025 driven by strong growth in its international markets like Singapore and Hong Kong. Key Financial Highlights: Total Revenue: US$175.2 million a XXXX% increase year-over-year (YoY). Non-GAAP Net Income: US$57.0 million approximately XXX times the level YoY also a record high. Total Client Assets: Hit a new peak of US$61.0 billion up XXXX% YoY. Operational Highlights:Funded Accounts: Added 31500 new funded clients bringing the total to XXXX million (up XXXX% YoY). Annual Target: The company already met its full-year target of"  
[X Link](https://x.com/seahorse_anton/status/1996675931084304824)  2025-12-04T20:20Z XX followers, XXX engagements


"2) The Quant Core: Near-Zero Risk This is the most important data point: Downside Probability (Loss): Only 2.4%. This is extremely rare for a stock in a downtrend. Neutral Probability: 87.7%. $RXRX is in a statistically low-volatility pocket. Downside is capped. This is the exact phase where patient buyers start watching"  
[X Link](https://x.com/seahorse_anton/status/1997034060653207981)  2025-12-05T20:03Z XX followers, XXX engagements


"Risk Levels + Whats Next: $TTR Key Levels & Risk Map Support: $3840 then $XX $XXXXX. Reversal requires: reclaiming $XX (Tenkan) $XX (Kijun). Below $XX Opens a fresh leg lower. Hybrid system still shows bearish macro trend + short-biased precision triggers. Bottom line: structure first sentiment later. Trend hasnt turned"  
[X Link](https://x.com/seahorse_anton/status/1997636459176563160)  2025-12-07T11:57Z XX followers, XX engagements


"@syndrome22q1 @catturd2 @GuntherEagleman @karolineleavitt @atensnut @lindayaX @dbongino @bennyjohnson @alphafox @MrBeast Merry Christmas Justin"  
[X Link](https://x.com/seahorse_anton/status/1998498055449137288)  2025-12-09T21:00Z XX followers, XX engagements


"$CRWV broke above resistance but daily cloud suggests sth. Trending towards neutral and the ML model only gives XX% breakout probability firmly in the possible but weak category. 4H momentum is strong - improving (MACD strong RSI elevated) but with a neutral cloud + Doji + VPT divergence the upside still lacks confirmation. Overall Mixed setup strong short-term buying pressure but higher-timeframe trend still not aligned. Guys who bought at XX are great. I missed (D) Daily Close: $XXXXX Support: $XXXXX Resistance: $XXXXX RSI: XXXX (neutral) MACD: XXXX bullish histogram (+2.90) OBV Z-Score:"  
[X Link](https://x.com/seahorse_anton/status/1996986632004657167)  2025-12-05T16:54Z XX followers, XXX engagements


"I ran simulations on Richtech Robotics $RR This is not like $ZETA or $OSCR where XX models tightly cluster. Here all upside-leaning forecasts come with catastrophic drawdowns: VaR losses 8096% Extreme volatility regime LSTM refusing to confirm trend Translation: Upside is possible but risk profile is explosive and asymmetric. 💡 My Take This is a high-variance lottery ticket not a trend-backed momentum setup. When ensembles split this far apart it signals uncontrolled volatility + weak signal reliability. If trading: Stop-loss: $XXXX (protect capital) Expect violent swings and unreliable"  
[X Link](https://x.com/seahorse_anton/status/1997758341406503073)  2025-12-07T20:01Z XX followers, XXX engagements


"🤝 Key Partnerships and Collaborations $MRNA Moderna strategically relies on collaborations to share R&D risk gain access to specialized technology and leverage commercial expertise outside of its core focus. $MERCK $VERTEX"  
[X Link](https://x.com/seahorse_anton/status/1998827960107737135)  2025-12-10T18:51Z XX followers, XX engagements


"💸 Revenue and Earnings from Royalty & Collaboration $MRNA Modernas revenue structure has dramatically shifted but royalties and collaboration income remain distinct components. The Revenue Shift Prior to 2020 Modernas revenue was primarily composed of Grant Revenue (from government agencies) and Collaboration Revenue (from pharma partners). Since 2021 the vast majority (over 95%) of its total revenue has come from Net Product Sales of its COVID-19 and RSV vaccines. Collaboration and Royalty Income :"  
[X Link](https://x.com/seahorse_anton/status/1998827964511756628)  2025-12-10T18:51Z XX followers, XX engagements


"e) Platform & Manufacturing Competition (The least discussed but most important moat.) Competitors/Peers: Other large mRNA companies (or those entering space) traditional biologics manufacturers gene-therapy firms scaling manufacturing. Challenge: As more competitors enter manufacturing costs and yield pressures increase. Regulatory oversight is growing (especially vaccines) which raises compliance cost. Opportunity: Modernas established mRNA production infrastructure and know-how give it a head start if it maintains cost discipline quality control and capacity expansion"  
[X Link](https://x.com/seahorse_anton/status/1998827993003700532)  2025-12-10T18:51Z XX followers, XX engagements


"3. 💉Research Pipeline and Clinical Focus: Phase X X and X $MRNA Modernas pipeline is divided into four strategic areas: Seasonal Vaccines Latent & Other Vaccines Oncology and Rare Disease Therapeutics. The strategy is currently focused on leveraging the cash generated from approved products to aggressively fund the development of its non-COVID portfolio. Phase X & Approved Programs Modernas late-stage pipeline is characterized by multiple respiratory vaccines aiming to build a large commercial franchise"  
[X Link](https://x.com/seahorse_anton/status/1998827946442723365)  2025-12-10T18:51Z XX followers, XX engagements


"Phase X Programs $MRNA These assets represent the mid-stage programs that will drive diversification beyond respiratory viruses"  
[X Link](https://x.com/seahorse_anton/status/1998827951161250102)  2025-12-10T18:51Z XX followers, XX engagements


"Key Competitors BioNTech / Pfizer Comparable mRNA capabilities; strong LNP technology. CureVac & Acuitas (Note: Curevac is now acquired by BionTech) Developing alternative mRNA and LNP systems. Regeneron $REGN Merck AstraZeneca $AZN Scaling biologics platforms that may compete indirectly by alternative modalities. Why this matters: Manufacturing scalability + cost of goods will determine long-term margins. mRNA vaccines must beat protein/subunit vaccines on economics not just speed. Moderna competes against world-class incumbents in every category vaccine giants in respiratory disease"  
[X Link](https://x.com/seahorse_anton/status/1998827997239935248)  2025-12-10T18:51Z XX followers, XXX engagements


"🧵 Why Recursion Pharma $RXRX Just Became a Deep Value Quant Play The Hook: The R/R Asymmetry Recursion Pharma RXRX just gave a massive structural signal. The Weekly Quant Score is NEUTRAL but the Probability-Weighted R/R exploded to 4.10x. This means: downside risk is statistically compressed while upside tails are widening. Something is changing in this downtrend"  
[X Link](https://x.com/seahorse_anton/status/1997034056999977156)  2025-12-05T20:03Z XX followers, XXX engagements


"Phase X Programs These are early-stage high-risk high-reward programs focused on diseases with major unmet needs"  
[X Link](https://x.com/seahorse_anton/status/1998827955540340952)  2025-12-10T18:51Z XX followers, XX engagements


"5. 💰 IPO & Fundamentals (Including Q3 2025 Report) $MRNA Modernas Initial Public Offering (IPO) in late 2018 was historic for the biotechnology sector demonstrating strong investor confidence in the unproven mRNA platform"  
[X Link](https://x.com/seahorse_anton/status/1998828001413247358)  2025-12-10T18:51Z XX followers, XX engagements